- The stock price of Jasper Therapeutics Inc (NASDAQ: JSPR) increased by over 139% during intraday trading today. This is why it happened.
The stock price of Jasper Therapeutics Inc (NASDAQ: JSPR) increased by over 139% during intraday trading today. Investors are responding positively to Oppenheimer analyst Jay Olson initiating coverage of Jasper Therapeutics with an “Outperform” rating and a $21 price target.
Olson views Jasper as an emerging leader in the development of novel targeted conditioning agents for hematopoietic stem cell transplantation with its lead candidate JSP191 and proprietary engineered hematopoietic stem cell platform. And the company is well-positioned to potentially transform the decades-old standard hematopoietic stem cell transplantation for various diseases either as a standalone conditioning agent or as the backbone of the conditioning regimen.
The $21 price target imputes a 191.26% upside in the company shares.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.